Treatment ofClostridium difficileinfection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model | Zendy

John H. Moore | Zendy; Edward J. van Opstal | Zendy; Glynis L. Kolling | Zendy; Jae Hyun Shin | Zendy; Elena Bogatcheva | Zendy; B. V. Nikonenko | Zendy; Leo Einck | Zendy; Andrew J. Phipps | Zendy; Richard L. Guerrant | Zendy; Marina Protopopova | Zendy; Cirle A. Warren | Zendy

Open Access

Treatment ofClostridium difficileinfection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model

Author(s) -

John H. Moore,

Edward J. van Opstal,

Glynis L. Kolling,

Jae Hyun Shin,

Elena Bogatcheva,

B. V. Nikonenko,

Leo Einck,

Andrew J. Phipps,

Richard L. Guerrant,

Marina Protopopova,

Cirle A. Warren

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv479

Subject(s) - clostridium difficile , disease , microbiology and biotechnology , medicine , clostridiaceae , antibiotics , clostridium infections , immunology , biology , toxin

Clostridium difficile infection (CDI) is a primary cause of antibiotic-associated diarrhoeal illness. Current therapies are insufficient as relapse rates following antibiotic treatment range from 25% for initial treatment to 60% for treatment of recurrence. In this study, we looked at the efficacy of SQ641 in a murine model of CDI. SQ641 is an analogue of capuramycin, a naturally occurring nucleoside-based compound produced by Streptomyces griseus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research